In new drug development for asthma therapy, the overwhelming interest of various highly specific complement inhibitors (C3a and C5a) for the demonstration of pathological mechanisms may not only uncover new candidates with therapeutic potential but also help discover even more fascinating cross-talk mechanisms between complement and other cellular parts of immunity. Here, C5AR1 is linked to asthma.